● First biological product launched in 1999
● 3 products launched, 2 have the largest market share in China
● Focusing on research and commercialization of recombinant protein drugs
from prokaryotic expression and mammalian cell expression
● Robust pipeline comprising biosimilars and innovative biologics
● Manufacturing facilities complying with cGMP requirements
● Dosage forms: ampoules, vials, pre-filled syringes, etc
Qilu Biopharmaceutical Industrial Park
● Total construction area covers 800,000 m2
● Being constructed in accordance with the requirements of USFDA cGMP/EU GMP
● Phase I construction completed and manufacture commenced. Manufacturing facilities are available for production of:
- Mammalian cell expression products
- Prokaryotic cell expression products
- Small molecule finished formulations